Page 90 - Read Online

Page 20 of 21 Toniutto et al. Hepatoma Res 2020;6:50 I http://dx.doi.org/10.20517/2394-5079.2020.40

an international consensus conference report. Lancet Oncol 2012;13:e11-22.
101. Yao FY, Mehta N, Flemming J, Dodge J, Hameed B, et al. Downstaging of hepatocellular cancer before liver transplant: long-term
outcome compared to tumors within Milan criteria. Hepatology 2015;61:1968-77.
102. Mehta N, Dodge JL, Grab JD, Yao FY. National experience on down-staging of hepatocellular carcinoma before liver transplant: influence
of tumor burden, alpha-fetoprotein, and Wait Time. Hepatology 2020;71:943-54.
103. Yao FY, Fidelman N. Reassessing the boundaries of liver transplantation for hepatocellular carcinoma: where do we stand with tumor
down-staging? Hepatology 2016;63:1014-25.
104. Heimbach JK, Kulik LM, Finn RS, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
105. Bruix J, Reig M, Sherman M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma.
Gastroenterology 2016;150:835-53.
106. European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL Clinical
Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018;69:182-236.
107. Bryce K, Tsochatzis EA. Downstaging for hepatocellular cancer: harm or benefit? Transl Gastroenterol Hepatol 2017;2:106.
108. Mehta N, Bhangui P, Yao FY, Mazzaferro V, Toso C, et al. Liver transplantation for hepatocellular carcinoma. Working Group Report
from the ILTS Transplant Oncology Consensus Conference. Transplantation 2020;104:1136-42.
109. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52-60.
110. Cucchetti A, Serenari M, Sposito C, Di Sandro S, Mosconi C, et al. Including mRECIST in the Metroticket 2.0 criteria improves
prediction of hepatocellular carcinoma-related death after liver transplant. J Hepatol 2020;73:342-8.
111. O’Malley ME, Takayama Y, Sherman M. Outcome of small (10-20 mm) arterial phase-enhancing nodules seen on triphasic liver CT in
patients with cirrhosis or chronic liver disease. Am J Gastroenterol 2005;100:1523-8.
112. Grasso A, Stigliano R, Morisco F, Martines H, Quaglia A, et al. Liver transplantation and recurrent hepatocellular carcinoma: predictive
value of nodule size in a retrospective and explant study. Transplantation 2006;81:1532-41.
113. Onaca N, Davis GL, Jennings LW, Goldstein RM, Klintmalm GB. Improved results of transplantation for hepatocellular carcinoma: a
report from the international registry of hepatic tumors in liver transplantation. Liver Transpl 2009;15:574-80.
114. Decaens T, Roudot-Thoraval F, Badran H, Wolf P, Durand F, et al. Impact of tumour differentiation to select patients before liver
transplantation for hepatocellular carcinoma. Liver Int 2011;31:792-801.
115. Halazun KJ, Najjar M, Abdelmessih RM, Samstein B, Griesemer AD, et al. Recurrence after liver transplantation for hepatocellular
carcinoma: a new MORAL to the story. Ann Surg 2017;265:557-64.
116. Mehta N, Heimbach J, Harnois DM, Sapisochin G, Dodge JL, et al. Validation of a risk estimation of tumor recurrence after transplant
(RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017;3:493-500.
117. Verna EC, Patel YA, Aggarwal A, Desai AP, Frenette C, et al. Liver transplantation for hepatocellular carcinoma: Management after the
transplant. Am J Transplant 2020;20:333-47.
118. Goldaracena N, Mehta N, Scalera I, Sposito C, Atenafu EG, et al. Multicenter validation of a score to predict prognosis after the
development of HCC recurrence following liver transplantation. HPB (Oxford) 2019;21:731-8.
119. Sapisochin G, Goldaracena N, Astete S, Laurence JM, Davidson D, et al. Benefit of treating hepatocellular carcinoma recurrence after
liver transplantation and analysis of prognostic factors for survival in a large euro-american series. Ann Surg Oncol 2015;22:2286-94.
120. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, et al. Living donor versus deceased donor liver transplantation for early irresectable
hepatocellular carcinoma. Br J Surg 2007;94:78-86.
121. Vakili K, Pomposelli JJ, Cheah YL, Akoad M, Lewis WD, et al. Living donor liver transplantation for hepatocellular carcinoma: Increased
recurrence but improved survival. Liver Transpl 2009;15:1861-6.
122. Bhangui P, Vibert E, Majno P, Salloum C, Andreani P, et al. Intention-to-treat analysis of liver transplantation for hepatocellular
carcinoma: living versus deceased donor transplantation. Hepatology 2011;53:1570-9.
123. Sandhu L, Sandroussi C, Guba M, Selzner M, Ghanekar A, et al. Living donor liver transplantation versus deceased donor liver
transplantation for hepatocellular carcinoma: comparable survival and recurrence. Liver Transpl 2012;18:315-22.
124. Xiao GQ, Song JL, Shen S, Yang JY, Yan LN. Living donor liver transplantation does not increase tumor recurrence of hepatocellular
carcinoma compared to deceased donor transplantation. World J Gastroenterol 2014;20:10953-9.
125. Park MS, Lee KW, Suh SW, You T, Choi Y, et al. Living-donor liver transplantation associated with higher incidence of hepatocellular
carcinoma recurrence than deceased-donor liver transplantation. Transplantation 2014;97:71-7.
126. Gu XQ, Zheng WP, Teng DH, Sun JS, Zheng H. Impact of non-oncological factors on tumor recurrence after liver transplantation in
hepatocellular carcinoma patients. World J Gastroenterol 2016;22:2749-59.
127. Yang ZF, Poon RT, Luo Y, Cheung CK, Ho DW, et al. Up-regulation of vascular endothelial growth factor (VEGF) in small-for-size liver
grafts enhances macrophage activities through VEGF receptor 2-dependent pathway. J Immunol 2004;173:2507-15.
128. Man K, Lo CM, Xiao JW, Ng KT, Sun BS, et al. The significance of acute phase small-for-size graft injury on tumor growth and
invasiveness after liver transplantation. Ann Surg 2008;247:1049-57.
129. Shi JH, Huitfeldt HS, Suo ZH, Line PD. Growth of hepatocellular carcinoma in the regenerating liver. Liver Transpl 2011;17:866-74.
130. Kulik L, Abecassis M. Living donor liver transplantation for hepatocellular carcinoma. Gastroenterology 2004;127:S277-82.
131. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, et al. Hepatocellular carcinoma recurrence and death following living and
deceased donor liver transplantation. Am J Transplant 2007;7:1601-8.
132. Grat M, Kornasiewicz O, Lewandowski Z, Skalski M, Zieniewicz K, et al. The impact of surgical technique on the results of liver